|
Elanco Animal Health Incorporated, a global leader in animal health, announced US Department of Agriculture (USDA) approval of TruCan Ultra B (Oral), an oral vaccine to protect against Bordetella bronchiseptica in dogs. Building on TruCan B Oral, the first oral Bordetella vaccine to market, this line extension delivers the same proven protection in half the volume. Made with advanced PureFil Technology, Tru vaccines are designed to reduce adverse reactions by removing unwanted protein and debris and to improve patient comfort.
Bordetella bronchiseptica is one of the leading causes of canine infectious respiratory disease complex (CIRDC), commonly called “kennel cough” which can lead to coughing and other respiratory signs in exposed dogs. Research shows that expectations for the pet vaccination experience are evolving with 99% of pet owners considering it important their veterinarian use highly purified lower volume vaccines designed for a more comfortable experience. TruCan Ultra B (Oral) offers a practical, effective, and low stress experience for dogs.
TruCan Ultra B (Oral) was proven safe in a field study, representing client-owned dogs that ranged from 4 weeks to 15 years old and a broad selection. In addition, there was a 93% preventable fraction in a challenge study, demonstrating significant protection against cough associated with Bordetella bronchiseptica.
“We are committed to improving the in-clinic vaccination experience for pets,” said Bobby Modi, executive vice president, US Pet Health and Global Digital Transformation at Elanco. “USDA approval of TruCan Ultra B (Oral) strengthens our respiratory vaccine portfolio and demonstrates how Elanco is going beyond to develop innovative solutions that support better experiences for dogs and the veterinary teams who care for them.”
This is the second recent expansion of Elanco’s Tru vaccine line, with TruCan Ultra CIV H3N2/H3N8 receiving USDA approval in July of 2025.
Elanco’s Tru vaccine line is the first vaccine portfolio recommended by Fear Free, an organization whose mission is to prevent and alleviate fear, anxiety and stress in pets by inspiring and educating the people who care for them.
“Reducing fear and anxiety during the pet vaccination experience is a critical part of our goal at Fear Free,” said Dr. Marty Becker, founder, Fear Free. “I look forward to seeing the positive impact TruCan Ultra B (Oral) has on the in-clinic vaccination experience for dogs.”
TruCan Ultra B (Oral) is expected to launch in Q1 2026.
Elanco Animal Health Incorporated is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole.
|